XTX Topco Ltd bought a new stake in shares of Cardlytics, Inc. (NASDAQ:CDLX – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 12,978 shares of the company’s stock, valued at approximately $107,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quadrature Capital Ltd acquired a new position in shares of Cardlytics during the first quarter valued at approximately $1,906,000. General Equity Holdings LP increased its position in shares of Cardlytics by 31.0% during the 4th quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock valued at $5,748,000 after purchasing an additional 147,843 shares during the period. Vanguard Group Inc. raised its stake in shares of Cardlytics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock worth $32,046,000 after buying an additional 57,805 shares in the last quarter. Clear Street Markets LLC acquired a new stake in shares of Cardlytics in the fourth quarter valued at $199,000. Finally, Virtu Financial LLC bought a new position in Cardlytics during the fourth quarter valued at about $219,000. 68.10% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, COO Amit Gupta sold 22,699 shares of the company’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $8.66, for a total value of $196,573.34. Following the transaction, the chief operating officer now owns 150,569 shares in the company, valued at approximately $1,303,927.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Scott A. Hill acquired 40,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the completion of the acquisition, the director now owns 40,000 shares in the company, valued at $143,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Amit Gupta sold 22,699 shares of the business’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $8.66, for a total value of $196,573.34. Following the completion of the transaction, the chief operating officer now owns 150,569 shares in the company, valued at approximately $1,303,927.54. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.
Cardlytics Stock Down 2.8 %
Cardlytics (NASDAQ:CDLX – Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.12. The company had revenue of $69.64 million for the quarter, compared to the consensus estimate of $75.39 million. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The company’s revenue was down 9.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.57) EPS. As a group, equities research analysts anticipate that Cardlytics, Inc. will post -1.72 EPS for the current year.
Analysts Set New Price Targets
CDLX has been the subject of a number of research analyst reports. Bank of America downgraded shares of Cardlytics from a “neutral” rating to an “underperform” rating and cut their price target for the company from $4.00 to $3.50 in a report on Thursday, August 15th. Northland Securities cut shares of Cardlytics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $7.00 to $5.00 in a report on Friday, August 16th. Northland Capmk lowered shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Craig Hallum downgraded Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Finally, Needham & Company LLC cut Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating and five have given a hold rating to the stock. According to data from MarketBeat, Cardlytics presently has a consensus rating of “Hold” and a consensus target price of $7.50.
View Our Latest Analysis on CDLX
Cardlytics Profile
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Articles
- Five stocks we like better than Cardlytics
- The How And Why of Investing in Oil Stocks
- Why Lennar Stock Could Be the Best Play in the Housing Market
- When to Sell a Stock for Profit or Loss
- 2 Energy Stocks Fueling the AI Datacenter Boom
- 3 Warren Buffett Stocks to Buy Now
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Want to see what other hedge funds are holding CDLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardlytics, Inc. (NASDAQ:CDLX – Free Report).
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.